SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Agile Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

<u>00847L308</u> (CUSIP Number)

<u>July 10, 2024</u>

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

(Date of Event Which Requires Filing of This Statement)

	Page 1 of 8 Pages
	required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the
	of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for mendment containing information which would alter the disclosures provided in a prior cover page.
	Rule 13d-1(d)
\boxtimes	Rule 13d-1(c)
	Rule 13d-1(b)

CUSIP No. 00847L308				13G	Page 2 of 8 Pages	
1	NAMES OF REPORTI I.R.S. IDENTIFICATION			RSONS (ENTITIES ONLY)		
	TANG CAPITAL PARTNERS, LP					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [(b) [
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SOLE VOT	ING POWER			
		6	SHARED V 426,153	OTING POWER		
		7		OSITIVE POWER		
		8		ISPOSITIVE POWER		
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
10	426,153 CHECK BOX IF THE	AGGREGA	TE AMOUNT	IN ROW (9) EXCLUDES CERTAIN SH	ARES	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	6.2% TYPE OF REPORTING PERSON					
PN						

Page 2 of 8 Pages

CUSIP No. 00847L308				13G	Page 3 of 8 Pages	
1	NAMES OF REPORTIN I.R.S. IDENTIFICATION TANG CAPITAL MANA	N NOS. O	F ABOVE PER	RSONS (ENTITIES ONLY)		
2	CHECK THE APPROPI	RIATE BO	X IF A MEME	BER OF A GROUP*	(a) □ (b) ⊠	
3	SEC USE ONLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE					
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		0 SHARED V 426,153 SOLE DISPO	OTING POWER OSITIVE POWER ISPOSITIVE POWER		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 426,153					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.2%					
12	TYPE OF REPORTING PERSON OO					

Page 3 of 8 Pages

CUSIP No. 00847L308				13G	Page 4 of 8 Pages	
1	NAMES OF REPORTI I.R.S. IDENTIFICATIO KEVIN TANG			RSONS (ENTITIES ONLY)		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)					
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SOLE VOTI	ING POWER			
		6	426,153	OTING POWER		
		7	SOLE DISP	OSITIVE POWER		
		8	SHARED D 426,153	ISPOSITIVE POWER		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 426,153					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.2%					
12	TYPE OF REPORTING PERSON IN					

Page 4 of 8 Pages

Item 1(a). Name of Issuer:

Agile Therapeutics, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

500 College Road East, Suite 310, Princeton, NJ 08540

Item 2(a). Name of Person Filing:

This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin Tang, the manager of Tang Capital Management.

Item 2(b). Address of Principal Business Office or, if none, Residence:

4747 Executive Drive, Suite 210, San Diego, CA 92121

Item 2(c). Citizenship:

Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.0001 per share (the "Common Stock")

Item 2(e). CUSIP Number 00847L308

Item 3. Not applicable.

Item 4. Ownership.

(a) Amount Beneficially Owned:

Tang Capital Partners. Tang Capital Partners beneficially owns 426,153 of the Issuer's Common Stock.

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

Tang Capital Management. Tang Capital Management beneficially owns 426,153 of the Issuer's Common Stock.

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

Kevin Tang. Kevin Tang beneficially owns 426,153 of the Issuer's Common Stock.

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

	Tang (Capital Partners	6.2%			
Tang Capital Management Kevin Tang			6.2%			
		Tang	6.2%			
(c)	Numb	er of shares as to which such person has	S:			
	(i) sole power to vote or to direct th		ote:			
		Tang Capital Partners	0 shares			
		Tang Capital Management	0 shares			
		Kevin Tang	0 shares			
	(ii)	shared power to vote or to direct the	vote:			
		Tang Capital Partners	426,153 shares			
		Tang Capital Management	426,153 shares			
		Kevin Tang	426,153 shares			
	(iii)	sole power to dispose or to direct the	e disposition of:			
		Tang Capital Partners	0 shares			
		Tang Capital Management	0 shares			
		Kevin Tang	0 shares			
	(iv)	shared power to dispose or to direct	the disposition of:			
		Tang Capital Partners	426,153 shares			
		Tang Capital Management	426,153 shares			
		Kevin Tang	426,153 shares			
Own	ership (of Five Percent or Less of a Class.				
		ent is being filed to report the fact that five percent of the class of securities, c	as of the date hereof the reporting person has ceased to be the beneficial owner check the following: \Box			
Own	ership (of More than Five Percent on Behalf	of Another Person.			
Not a	Not applicable					
Iden	tificatio	n and Classification of the Subsidiary	y Which Acquired the Security Being Reported on by the Parent Holding Company.			
Not a	applicab	le.				
Iden	tificatio	n and Classification of Members of the	he Group.			
Not a	Not applicable.					
Noti	ce of Di	ssolution of Group.				
Not a	applicab	le.				
	Page 6 of 8 Pages					

The percentages used herein are based on 6,904,498 shares of Common Stock outstanding as of July 8, 2024, as set forth in the Issuer's

Proxy Statement filed on Schedule 14A that was filed with the Securities and Exchange Commission on July 12, 2024.

(b)

Item 5.

Item 6.

Item 7.

Item 8.

Item 9.

Percent of Class:

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 7 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:	July 22, 2024	
-		
TANG	CAPITAL PARTNERS, LP	
By: Ta	ng Capital Management, LLC, its General Partner	
By:	/s/ Kevin Tang	
_	Kevin Tang, Manager	
TANG	CAPITAL MANAGEMENT, LLC	
By:	/s/ Kevin Tang	
-	Kevin Tang, Manager	
/s/ Kev	vin Tang	
Kevin		
	-	
		Page 8 of 8 Pages

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, \$0.0001 par value per share, of Agile Therapeutics, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Date: July 22, 2024

TANG CAPITAL PARTNERS, LP

By: Tang Capital Management, LLC

Its: General Partner

By: /s/ Kevin Tang

Name: Kevin Tang Title: Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang

Name: Kevin Tang Title: Manager

/s/ Kevin Tang

Name: Kevin Tang